Dr. Edmund Tsui and author Dr. Douglas A. Jabs discuss the results of the ADVISE Trial, designed to compare adalimumab to conventional immunosuppressive drugs for the treatment of non-infectious intermediate, posterior, and panuveitides. From Dr. Jab's Ophthalmology article, "<a href= "https://www.aaojournal.org/article/S0161-6420(25)00639-6/fulltext">Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial</a>." Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial. Jabs, Douglas A. et al. Ophthalmology. In press. Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at <a href= "https://store.aao.org/ophthalmology-virtual-journal-club.html">https://store.aao.org/ophthalmology-virtual-journal-club.html</a>

GLP-1RA Use and Risk of Neovascular AMD

Join Ophthalmology's social media editors as they interview authors and editors of the American Academy of Ophthalmology's journal family: Ophthalmology, Ophthalmology Retina, Ophthalmology Glaucoma, and Ophthalmology Science.